US Patent No. 9,878,031

COMPOSITIONS, METHODS OF ADMINISTRATION AND USES FOR TRIVALENT DENGUE VIRUS FORMULATIONS


Patent No. 9,878,031
Issue Date January 30, 2018
Title Compositions, Methods Of Administration And Uses For Trivalent Dengue Virus Formulations
Inventorship Dan T. Stinchcomb, Fort Collins, CO (US)
Joseph N. Brewoo, Madison, WI (US)
Jorge E. Osorio, Mount Horeb, WI (US)
Charalambos D. Partidos, Chicago, IL (US)
Assignee Takeda Vaccines, Inc., Cambridge, MA (US)

Claim of US Patent No. 9,878,031

1. A method for inducing neutralizing antibodies in a subject against three or more dengue virus serotypes, the method comprising;
administering a first dose of a single trivalent dengue virus immunogenic composition comprising a mixture of three or more
different live, attenuated dengue viruses, wherein the mixture comprises at least three dengue virus serotypes comprising
dengue-dengue chimeras, wherein the dengue-dengue chimeras comprise dengue virus structural proteins on an attenuated dengue-2
virus backbone, and one or more structural elements of dengue-1, dengue-2, dengue-3 or dengue-4, and one or more structural
or non-structural elements of a live, attenuated dengue virus, and wherein the attenuated dengue-2 virus comprises dengue-2
strain PDK-53, and wherein three of four dengue virus serotype structural elements are present in the single trivalent dengue
virus immunogenic composition; and

administering at least a second dose of a live, attenuated dengue virus immunogenic composition comprising a single live,
attenuated dengue virus chimera or a monovalent live, attenuated dengue virus on the same day or up to 180 days after administration
of the first dose of the single trivalent dengue virus immunogenic composition.